The Claim
In adults with cardiovascular disease but no diabetes, treatment with semaglutide over 34 months is associated with a lower rate of non-fatal myocardial infarction (2.7% vs 3.7%) compared to control, with a hazard ratio of 0.72 (95% CI 0.61–0.85), and this outcome was the only component of the primary composite endpoint to achieve statistical significance.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
For people with heart disease but not diabetes, taking semaglutide seems to lower the chance of having a non-fatal heart attack over about three years — 2.7% of users had one versus 3.7% who didn’t take it.
See the scientific wording
In adults with cardiovascular disease but no diabetes, semaglutide is associated with a lower rate of non-fatal myocardial infarction (2.7% vs 3.7%) over 34 months, with a hazard ratio of 0.72 (95% CI 0.61–0.85), representing the only component of the primary composite endpoint to show a statistically significant benefit.
What the research says
1 studyStudy: Semaglutide reduces the absolute risk of major cardiovascular events by 1.5%
The study looked at semaglutide in people with heart disease but not diabetes, and found it reduced heart attacks, just like the claim says.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.